This bill proposes to add 7-hydroxymitragynine to Schedule I of the Controlled Substances Act, classifying it as a controlled substance. The legislation specifically excludes naturally occurring 7-hydroxymitragynine found in kratom plants from this classification while including synthetic versions. This change would require federal regulation of synthetic forms of the compound but would not affect kratom products containing the substance in its natural state. The bill directly impacts pharmaceutical manufacturers and synthetic drug producers who would need to comply with new federal scheduling requirements.
HR 589, the FACE Act Repeal Act of 2025, would repeal a federal law (Section 248 of Title 18, U.S. Code) that prohibited obstructing access to reproductive health care facilities through physical means, intimidation, or violence. This repeal would eliminate the federal criminal penalty for such conduct, meaning federal prosecutors could no longer charge individuals under this specific law. The bill applies to all pending or future federal prosecutions related to these actions. It does not affect state laws that may still regulate access to reproductive health care facilities.
HR 215, the Adoption Information Act, requires family planning services funded under Title V of the Social Security Act to provide pamphlets containing regional adoption center contact information to patients inquiring about medical or abortion services. Specifically, medical professionals must offer a pamphlet listing all adoption centers in the region with their addresses and phone numbers at the time of inquiry, and ensure patients have the opportunity to read it. The Secretary of Health and Human Services must annually update and distribute these pamphlets to all qualifying family planning programs. This provision uses existing Title V funding, with no new funds required for implementation.
HR 119 prohibits organizations receiving federal funds from the CARES Act, American Rescue Plan, or other specified COVID relief packages from mandating employee COVID-19 vaccinations. It applies to entities that received funds under six major relief bills, including the CARES Act (2020) and American Rescue Plan (2021). Violating this rule requires the entity to return all received funds to the government. The law directly affects businesses, nonprofits, and public entities that received these specific relief payments.
HR 120, the No Mandates Act, bans federal agencies and entities receiving certain federal funds from requiring individuals to get a COVID-19 vaccine. It prohibits agencies from issuing any rules mandating the vaccine and forbids requiring vaccination for access to federal property, services, or congressional grounds. Entities receiving funds from specific COVID-19 relief packages (like the CARES Act or American Rescue Plan) cannot require vaccination as a condition for providing services, and must return all federal funds if they violate this rule. The bill directly affects federal agencies, government contractors, and organizations like hospitals or businesses that received pandemic relief funds.
Freedom from Mandates Act This bill nullifies certain executive orders regarding COVID-19 safety and prohibits the Departments of Labor and Health and Human Services (HHS) from taking specified actions with respect to vaccination against COVID-19. Specifically, the bill nullifies Executive Order 14042 (relating to ensuring adequate COVID-19 safety protocols for federal contractors) and Executive Order 14043 (requiring COVID-19 vaccination for federal employees). Labor may not issue any rule requiring employers to mandate vaccination of employees against COVID-19 or requiring testing of employees who are unvaccinated. HHS may not (1) require a health care provider, as a condition of participation in the Medicare or Medicaid program, to mandate vaccination of employees against COVID-19 or require testing of employees who are unvaccinated; or (2) otherwise penalize such a provider for failure to mandate such vaccination or require such testing.
HR 87, the "Protecting Our Children from the CDC Act," requires the CDC to publicly post all clinical safety and effectiveness data for any COVID-19 vaccine before it can be added to the official child and adolescent immunization schedule. It automatically removes all currently listed COVID-19 vaccines from that schedule upon the bill's enactment. The bill mandates that all posted data must be de-identified to protect privacy. This applies specifically to the CDC's Advisory Committee on Immunization Practices (ACIP) schedule and affects how future CDC vaccine recommendations for children are made. The law does not alter the CDC's authority to later reinstate a vaccine if the required data is posted.
HR 1785, the Preventing Medicare Telefraud Act, requires doctors to have seen Medicare patients in person at least once within the past six months before ordering high-cost durable medical equipment or laboratory tests via telehealth. This applies to services covered under Medicare, directly affecting providers who frequently use telehealth for these specific high-cost items. The bill mandates Medicare contractors to audit providers ordering 90% or more of such equipment or tests via telehealth, and also requires providers to submit their National Provider Identifier (NPI) when billing for telehealth services. These provisions aim to prevent potential fraud by ensuring in-person evaluations precede telehealth orders for expensive medical items.
This bill requires physicians performing abortions to have hospital admitting privileges within 15 miles of the procedure location and to inform patients about nearby facilities for follow-up care if complications arise. It also sets conditions for abortion clinics receiving federal funds, mandating state licensing and compliance with outpatient surgery center standards (excluding certificate-of-need requirements). Violations by physicians could result in fines or up to two years in prison. The bill directly affects healthcare providers and clinics, not pregnant patients, and amends Title 18 of the U.S. Code to establish these requirements.
The Second Chance for Moms Act (HR 796) requires a new warning label on mifepristone - a medication used for medical abortions - stating that natural progesterone may counteract its effects and increase fetal survival, with a hotline reference for further information. It also mandates a federal 24/7 hotline providing support and referrals exclusively to healthcare providers offering "abortion pill reversal" services. This bill directly affects patients prescribed mifepristone and healthcare providers who dispense the medication, as the label must appear on packaging and the hotline must be established. The warning label would take effect six months after enactment, and the hotline would operate under the Public Health Service Act.
